文献速递血脂与心血管预防

载脂蛋白B-100氧化磷脂与卒中或短暂性脑缺血发作后复发性缺血事件

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

在SPARCL试验中,基线OxPL-apoB升高的卒中或短暂性脑缺血发作患者复发性卒中风险更高(HR 4.3),首次主要冠脉事件风险也更高(HR 4.0)。在他汀治疗基础上,OxPL-apoB与治疗无交互作用,提示其可能是他汀非依赖性治疗靶点。

要点

  • 复发性卒中患者基线中位OxPL-apoB水平高于无复发者(15.5 vs 11.6 nmol/l;p<0.0001)。
  • 校正后基线OxPL-apoB升高预测复发性卒中(HR 4.3)、首次主要冠脉事件(HR 4.0)及任何心血管事件(HR 4.4)。
  • OxPL-apoB与治疗无交互作用(交互检验无统计学意义),提示其可能是他汀非依赖性治疗靶点。

核心结论

  • 在有卒中或短暂性脑缺血发作病史的患者中,基线OxPL-apoB水平升高可预测复发性卒中和首次主要冠脉事件。

研究设计与样本

  • SPARCL试验中,4,385例卒中或短暂性脑缺血发作患者在基线时测量OxPL-apoB,其中3,106例在随机分组后5年时复测。
  • 患者被随机分配至安慰剂组或80 mg阿托伐他汀组。
  • 主要终点为随机分组至第二次非致死性或致死性卒中的时间。

主要发现

  • 复发性卒中患者基线中位OxPL-apoB水平为15.5 nmol/l,无复发性卒中患者为11.6 nmol/l(p<0.0001)。
  • 多变量校正后,基线OxPL-apoB升高预测复发性卒中(HR 4.3;p<0.0001)。
  • 基线OxPL-apoB升高预测首次主要冠脉事件(HR 4.0;p<0.0001)和任何心血管事件(HR 4.4;p<0.0001)。
  • 任何终点的比较在各治疗组间均无差异,表现为交互检验无统计学意义。
  • 将OxPL-apoB加入模型后,净重分类改善、综合判别改善和受试者工作特征曲线下面积(AUC)均显著改善:复发性卒中ΔAUC +0.0505(p<0.0001),首次主要冠脉事件ΔAUC +0.0409(p<0.0001),任何心血管事件ΔAUC +0.0791(p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers to predict recurrent stroke and targets of therapy to prevent stroke are lacking. OBJECTIVES: This study evaluated whether patients with prior cerebrovascular events and elevated levels of oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB), but without prior coronary artery disease (CAD), are at risk for recurrent stroke and CAD events following high-dose statin therapy. METHODS: In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, OxPL-apoB levels were measured in 4,385 patients with stroke or transient ischemic attack at baseline and in 3,106 patients at 5 years following randomization to placebo or 80 mg atorvastatin. The primary endpoint was the time from randomization to a second nonfatal or fatal stroke. Secondary endpoints included first major coronary events and any cardiovascular event. RESULTS: Patients with recurrent stroke had higher baseline median OxPL-apoB levels than patients without (15.5 nmol/l vs. 11.6 nmol/l; p < 0.0001). After multivariable adjustment, elevated baseline OxPL-apoB predicted recurrent stroke (hazard ratio [HR]: 4.3; p < 0.0001), first major coronary events (HR: 4.0; p < 0.0001), and any cardiovascular event (HR: 4.4; p < 0.0001). These comparisons for any endpoint did not differ by treatment, shown as a nonsignificant interaction test. The net reclassification improvement, integrated discrimination improvement, and area under the receiver-operating characteristic curve (AUC) were all significantly improved by adding OxPL-apoB to the models, with ΔAUC +0.0505 (p < 0.0001) for recurrent stroke, ΔAUC +0.0409 (p < 0.0001) for first major coronary event, and ΔAUC +0.0791 (p < 0.0001) for any cardiovascular event. CONCLUSIONS: Elevated OxPL-apoB levels predicted recurrent stroke and first major coronary events in patients with prior stroke or transient ischemic attack. The lack of statin-OxPL-apoB treatment interaction suggested that OxPLs might be statin-independent therapeutic targets to reduce risk of cardiovascular events. (Lipitor in the Prevention of Stroke, for Patients Who Have Had a Previous Stroke [SPARCL]; NCT00147602).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Byun YS, Yang X, Bao W, et al. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol. 2017. PMID: 28081824. doi:10.1016/j.jacc.2016.10.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。